Roche announces start of second part of Phase 2 clinical trials for SUNFISH

SUNFISHWe are pleased to share with you that Roche has announced that the dose selection for part 2 of the SUNFISH trial has been confirmed. This marks the start of part 2 of Phase 2 in SUNFISH.

Sunfish examines RG7916 in people aged 2 – 25 years with Type 2/3 SMA. The trials are taking place in Belgium, France, Italy and Germany.


community update – September 2017

About RG7916

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.